

CO-SIGNERS TO THE LETTER CONCERNING IMMIGRATION*

FEBRUARY 6, 2017

	FIRST	MIDDLE	LAST	TITLE	COMPANY
1	Julian		Adams	Chief Science Officer, President	Cia1 Biotechnology Industries (CBI)
2	Chris		Adams	Chief Executive Officer	Cydan Development Inc.
3	Brett		Ahrens	General Partner	Caanan Partners
4	Jeff		Albers	President & CEO	Blueprint Medicines
5	Mara	G.	Aspinall	CEO	Health Catalysts
6	James	E.	Audia	Chief Scientific Officer	Constellation Pharmaceuticals, Inc.
7	Martin		Babler	CEO	Principia Biopharma
8	Peter		Barrett	Partner	Atlas Venture
9	Zoe		Barry	CEO & Founder	ZappRx
10	Nessan		Bermingham	Founder & CEO	Intellia Therapeutics
11	Stephen		Bloch	General Partner	Caanan Partners
12	Robert	I.	Blum	President & CEO	Cytokinetics, Inc.
13	Paul	B.	Bolno	President & CEO	Wave Life Sciences
14	Michael	W.	Bonney	Chair of the Board	Alnylam Pharmaceuticals
15	Bruce		Booth	Partner	Atlas Venture
16	Daniel	M.	Bradbury	Former President & CEO	Amylin Pharmaceuticals
17	Steven	K.	Brauer	Chairman	Salus Discovery LLC
18	Brook		Byers		Biotech Venture Capitalist since 1978
19	Pablo	J.	Cagnoni	President & CEO	Tizona Therapeutics, Inc
20	Brian	M.	Cali	Founder and SVP, Preclinical R&D	Ironwood Pharmaceuticals
21	Isaac		Ciechanover	Founder, CEO & President	Atara Bio
22	Chip		Clark	President & CEO	Genocea Biosciences, Inc.
23	Michael	D.	Clayman	CEO	Flexion Therapeutics
24	Jeff	L.	Cleland	President & CEO	Graybug Vision
25	Paula		Cobb	EVP Corporate Development	Decibel Therapeutics
26	Ron		Cohen	President & CEO	Acorda Therapeutics, Inc.
27	Ron		Cooper	President & CEO	Albireo Pharma Inc.
28	Mark	G.	Currie	President of R&D and Chief Scientific Officer	Ironwood Pharmaceuticals
29	Bassil		Dahiyat	President & CEO	Xencor
30	John		Diekman	Managing Partner	5AM Ventures
31	Eric	L.	Dobmeier	Chief Operating Officer	Seattle Genetics
32	Doug		Doerfler	Founder, President and CEO	MaxCyte, Inc.
33	Deborah		Dunsire	Principal	Southern Cross Biotech Consulting
34	Matthew		During	Founder & President	Ovid Therapeutics
35	Jens	W.	Eckstein	President	SR One
36	Eric		Elenko	Chief Research & Strategy Officer	PureTech Health
37	Neil	A.	Exter	Partner	Third Rock Ventures
38	Jonathan	J.	Fleming	President & CEO	Q-State Biosciences
39	Gregory	J.	Flesher	President & CEO	OticPharma Inc.
40	Jean-Francois		Formela	Partner	Atlas Venture
41	Robert		Forrester	President & CEO	Verastem Inc.
42	Cedric		Francois	President & CEO	Apellis Pharmaceuticals
43	Heather		Franklin	President & CEO	Blaze Bioscience Inc.
44	Mason	W.	Freeman	Venture Partner	5AM Ventures
45	Leonard	Patrick	Gage	Chairman	Tetraphase
46	Nicholas		Galakatos	Managing Director	Clarus
47	James	A.	Geraghty	Chairman	Juniper Pharmaceuticals
48	Simba		Gill	CEO	Evelo Biosciences
49	David	V.	Goeddel	Managing Partner	The Column Group
50	Mark	A.	Goldsmith	President & CEO	Revolution Medicines, Inc.
51	Maxine		Gowen	President & CEO	Trevena Inc.
52	Tom		Graney	CFO	Ironwood Pharmaceuticals
53	David		Grayzel	Partner	Atlas Venture
54	Barry		Greene	President	Alnylam Pharmaceuticals
55	Paul		Grint	President & CEO	Regulus Therapeutics
56	JC		Gutierrez-Ramos	CEO	Synlogic
57	Tuan		Ha-Ngoc	Executive Chairman	KEW, Inc.

*We received additional signatures after the deadline and will attempt to add them.

CO-SIGNERS TO THE LETTER CONCERNING IMMIGRATION*

FEBRUARY 6, 2017

	FIRST	MIDDLE	LAST	TITLE	COMPANY
58	Bill		Haney	Chief Executive Officer	Dragonfly Therapeutics, Inc.
59	Faheem		Hasnain	CEO/Chairman	FSG Biotech
60	Paul	J.	Hastings	Chairperson & CEO	OncoMed Pharmaceuticals
61	Yujiro	Steve	Hata	Co-Founder and CEO	IDEAYA Biosciences
62	Peter		Hecht	CEO	Ironwood Pharmaceuticals
63	Rich		Heyman	Executive Chairman and Co-Founder	Metacrine, Inc.
64	Steven	H.	Holtzman	President & CEO	Decibel Therapeutics
65	Herve		Hoppenot	CEO	Incyte
66	H. Robert		Horvitz	David H. Koch Professor of Biology	Massachusetts institute of Technology
67	Thomas	E.	Hughes	President & CEO	Zafgen, Inc.
68	Wende	S.	Hutton	General Partner	Caanan Partners
69	Annalisa		Jenkins	CEO	Dimension Therapeutics
70	Rachel		King	Chief Executive Officer	GlycoMimetics, Inc
71	Vanessa		King	President & CEO	Luc Therapeutics, Inc
72	Nina		Kjellson	General Partner	Caanan Partners
73	Gerhard		Koenig	President & CEO	Quartet Medicine
74	Scott		Koenig	President & CEO	MacroGenics, Inc.
75	Peter		Kolchinsky	Managing Partner	RA Capital Management, LLC
76	Paul		Laikind	President & CEO	ViaCyte, Inc.
77	Robert (Bob)		Langer	David H. Koch Institute Professor	Massachusetts Institute of Technology
78	John	J.	Lee	SVP, PharmDev	Decibel Therapeutics
79	Jonathan	S.	Leff	Partner	Deerfield Management
80	Nick		Leschly	President & CEO	Bluebird Bio
81	Jeremy	M.	Levin	Chairman & CEO	Ovid Therapeutics
82	Mark		Levin	Co-Founder	Third Rock Ventures
83	Arnold	J.	Levine	Professor Emeritus	Institute for Advanced Study
84	Alan		Levy	CEO	Chrono Therapeutics
85	David	R.	Liu	Co-Founder	Editas Medicine
86	Harvey	F.	Lodish	Founding Member	Whitehead Institute MIT
87	Uri		Lopatin	Chief Medical Officer	Assembly Biosciences
88	Ted	W.	Love	President	Global Blood Therapeutics
89	Guy		Macdonald	President & CEO	Tetraphase
90	Gail	J.	Maderis	President & CEO	Antiva Biosciences, Inc.
91	Ankit		Mahadevia	Co-Founder and CEO	Spero Therapeutics
92	Nagesh	K.	Mahanthappa	CEO & President	Scholar Rock
93	John		Maraganore	Chief Executive Officer	Alnylam Pharmaceuticals
94	Joel	F.	Martin	President & CEO	Dauntless Pharmaceuticals, Inc.
95	W. Eddie		Martucci	Co-Founder & CEO	Akili Interactive
96	James	G.	McArthur	Founder, President & CEO	Imara
97	Corey	M.	McCann	Chief Executive Officer	Pear Therapeutics
98	Sean	A.	McCarthy	President & CEO	CytomX
99	C. Geoffrey		McDonough	President & CEO	Sobi
100	John		Mendlein	Chief Executive Officer	aTyr Pharma
101	Diego		Miralles	President	Adaptive Biotechnologies
102	Kenneth	I.	Moch	President & CEO	Cognition Therapeutics, Inc.
103	Bob		Moore	Managing Director	Alta Partners
104	Andrew	G.	Myers	Amory Houghton Professor of Chemistry	Harvard University
105	Michael	A.	Narachi	President & CEO	Orexigen Therapeutics
106	Amir		Nashat	Managing Partner	Polaris Partners
107	William	J.	Newell	Chief Executive Officer	Sutro Biopharma, Inc.
108	Bernat		Olle	CEO	Vedanta Biosciences, Inc.
109	John	E.	Osborn	Board Member	Egalet
110	Julia	C.	Owens	Founder, President & CEO	Millendo Therapeutics, Inc.
111	Atul		Pande	President	Verity BioConsulting
112	H. Stewart		Parker	Principal	Parker BioConsulting
113	Kush	M.	Parmar	Managing Partner	5AM Ventures
114	Matthew	R.	Patterson	President & CEO	Audentes Therapeutics, Inc.

*We received additional signatures after the deadline and will attempt to add them.

CO-SIGNERS TO THE LETTER CONCERNING IMMIGRATION*

FEBRUARY 6, 2017

	FIRST	MIDDLE	LAST	TITLE	COMPANY
115	Steve	M.	Paul	President & CEO	Voyager Therapeutics, Inc.
116	Rob		Perez	Founder and Chairman	Life Science Cares
117	Matthew		Perry	President	BVF Partners, LP
118	Cary	G.	Pfeffer	Partner	Third Rock Ventures
119	Mike		Powell	General Partner	Sofinnova Ventures
120	Dennis	J.	Purcell	Founder & Senior Advisor	Aisling Capital LLC
121	Amit		Rakhit	Chief Medical & Portfolio Officer	Ovid Therapeutics
122	Kartik		Ramamoorthi	CEO	Encoded Genomics
123	William		Rastetter	Chairman	Neurocrine Biosciences Inc.
124	Adrian (Ad)		Rawcliffe	CFO	Adaptimmune
125	Laurence	E.	Reid	President & CEO	Warp Drive Bio
126	Jason	P.	Rhodes	Partner	Atlas Venture
127	William	J.	Rieflin	Chief Executive Officer	NGM Biopharmaceuticals, Inc.
128	Chad		Robins	CEO	Adaptive Biotechnologies
129	Scott	M.	Rocklage	Managing Partner	SAM Ventures
130	Michael		Rosenblatt	Chief Medical Officer	Flagship Pioneering
131	Jonathan	G.	Rosin	SVP Talent, Team & Culture	Ironwood Pharmaceuticals
132	William	J.	Rutter	Chairman	Synergenics, LLC
133	Saurabh		Saha	President & CEO	Delinia
134	Camille		Samuels	Partner	Venrock
135	Vicki	L.	Sato	Professor of Management Practice	Harvard Business School
136	George		Scangos	CEO & Director	Vir Bio
137	John	A.	Scarlett	President, CEO & Director	Geron Corporation
138	Stuart	L.	Schreiber	Morris Loeb Professor	Broad Institute
139	Andrew		Schwab	Managing Partner	SAM Ventures
140	Paul		Sekhri	President & CEO	Lycera Corporation
141	Thomas		Shenk	Professor of Molecular Biology	Lewis Thomas Laboratory
142	Clay	B.	Siegall	President & CEO	Seattle Genetics, Inc.
143	Nick	J.	Simon	Managing Director	Clarus Ventures LLC
144	Nancy		Simonian	CEO	Syros Pharmaceuticals
145	Jeff		Stein	President & CEO	Cidara Therapeutics
146	Michael		Su	CSO	Decibel Therapeutics
147	Mary	T.	Szela	Chief Executive Officer	Novelion Therapeutics
148	Nancy	A.	Thornberry	CEO	Kallyope
149	Martin		Tolar	Founder, President & CEO	Alzheon
150	Richard		Ulevitch	Venture Partner	SAM Ventures
151	Akshay	K.	Vaishnav	EVP R&D	Alnylam Pharmaceuticals
152	Anne		VanLent	President	AMV Advisors
153	George	P.	Vlasuk	President & CEO	Navitor Pharmaceuticals, Inc.
154	Michel		Vounatsos	Chief Executive Officer	Biogen
155	Samuel	G.	Waksal	Founder	MeiraGTx
156	Neil		Warma	President & CEO	Opexa Therapeutics, Inc.
157	Ryan	J.	Watts	Co-Founder & CEO	Denali Therapeutics Inc.
158	Yaron		Werber	Chief Business & Financial Officer	Ovid Therapeutics
159	Christoph		Westphal	Co-Founder, Chair & CEO	Flex Pharma
160	Wendell		Wierenga	Chairman of the Board	Crinetics Pharmaceuticals
161	Doug	E.	Williams	President & CEO	Codiak BioSciences
162	Lewis (Rusty)		Williams	Founder, CEO & Chairman	Five Prime Therapeutics, Inc.
163	Kleanthis	G.	Xanthopoulos	Managing General Partner	Cerus
164	Daphne		Zohar	Founder & CEO	PureTech Health
165	Sandford (Sandy)		Zweifach	President & CEO	Nuvelution Pharmaceuticals, Inc.

*We received additional signatures after the deadline and will attempt to add them.